We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Obinutuzumab
MedXY News
EnglishTag

Obinutuzumab

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with Obinutuzumab
Hematology-OncologyChemotherapy-freeIndolent B-cell NHL

Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with Obinutuzumab

By MedXY|Aug 17, 2026

A novel chemotherapy-free regimen combining mosunetuzumab with response-adapted polatuzumab vedotin and obinutuzumab shows high complete response rates and durable progression-free survival in untreated indolent B-cell NHL with favorable sa

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy
Nephrology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
FDA approval
lupus nephritis

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

By MedXY|Dec 18, 2025

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis managem

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma
Clinical UpdatesFollicular lymphomalenalidomide

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma

By MedXY|Oct 5, 2025

This phase 2 study demonstrates that obinutuzumab plus lenalidomide achieves high response rates with durable progression-free survival and manageable toxicities in untreated high tumor burden follicular lymphoma, suggesting a promising fro

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities